Medrol

Methylprednisolone, the active ingredient in Medrol, is a glucocorticoid presented as a tablet (various strengths) for oral use. It reduces inflammation and modulates immune responses in patients with autoimmune and allergic conditions.

GNH USA supplies Medrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medrol, a systemic glucocorticoid, is employed across several inflammatory and immune‑mediated disease groups.

- Rheumatoid arthritis: decreases joint swelling, pain, and structural damage. - Asthma exacerbations: rapidly improves airway inflammation and breathing function. - Allergic reactions: mitigates severe hypersensitivity symptoms such as hives and angioedema. - Dermatologic conditions: suppresses skin inflammation in disorders like eczema and psoriasis. - Autoimmune disorders: controls disease activity in conditions such as systemic lupus erythematosus.

Adverse reactions vary with dose and duration of therapy.

Common Side Effects: - Increased appetite and weight gain. - Elevated blood glucose levels. - Mood changes, including anxiety or insomnia. - Gastrointestinal discomfort or ulcer risk. - Fluid retention leading to mild edema.

Serious or Rare Side Effects: - Severe infections due to immune suppression. - Osteoporosis or bone fractures with long‑term use. - Adrenal insufficiency on abrupt discontinuation. - Vision problems such as cataracts or glaucoma. - Uncontrolled hypertension or cardiovascular events.

Before initiating Medrol, consider the following safety measures.

- Assess infection risk: screen for active or latent infections. - Monitor blood glucose: patients with diabetes may need dose adjustments. - Evaluate bone health: consider calcium and vitamin D supplementation. - Review psychiatric history: corticosteroids can exacerbate mood disorders. - Use caution in pregnancy: benefits must outweigh potential fetal risks. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise methylprednisolone levels. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal ulcer risk. - Diuretics: may worsen electrolyte imbalances. - Antidiabetic agents: may require dose escalation to maintain glycemic control.